Molecular Detection of
Neurodegenerative Diseases

Cognitact^® translates world-leading technology and innovative research into risk prediction, early detection, and disease surveillance tools for neurodegenerative diseases.

View Details

Molecular Detection of
Neurodegenerative Diseases

View Details

Molecular Detection of
Neurodegenerative Diseases

View Details

Top-notch Technology

Leverage on the cutting-edge proteomic detection method and machine learning algorithms, we have developed a proprietary scoring system for evaluating the disease risk based on the level changes of 21 blood biomarkers.

View Details

Top-notch Technology

View Details

Top-notch Technology

View Details

Blood Protein Detection

Only ~3 milliliters of blood are needed to obtain test results with an accuracy rate of over 96%

View Details

Blood Protein Detection

View Details

Blood Protein Detection

View Details

Ascertain the Risk
5-10 Years Prior to Onset

PlasmarkAD^®achieves early detection of Alzheimer’s disease at 5-10 years before symptoms appear.

View Details

Ascertain the Risk
5-10 Years Prior to Onset

View Details

Ascertain the Risk
5-10 Years Prior to Onset

View Details

What is Alzheimer's Disease?

Alzheimer's disease (AD) is a brain disorder that progressively impairs thinking skills and memory. It’s the most common type of dementia. The symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily life.

Symptoms

The symptoms of the disease including memory loss, cognitive decline, changes in mood and personality, language disability, sleep disorder, etc.

Therapeutic Methods

There is currently no cure for the disease. However, early intervention can temporarily improve symptoms or slow the progression of the disease.

Earlier Detection, Healthier Cognition.

We advocate for proactive measures for the earliest possible detection of Alzheimer’s disease, which is instrumental in facilitating a healthier cognitive state in patients and significantly improving their quality of life.

Delayed Diagnosis

Alzheimer’s disease (AD) mainly affects individuals above the age of 60. However, most patients are diagnosed only when significant symptoms appear, by which time serve brain atrophy have already occurred, causing them to miss the golden window of treatment.

Early Detection

It’s noteworthy that pathological changes in the brains of AD patients begin to occur 10-20 years before the onset of symptoms, indicating the potential of early diagnosis of AD. Studies have suggested that early diagnosis and intervention can reduce the risk of onset, delay onset and disease progression, and significantly enhance treatment efficacy.

Who Needs The Test?

Learn More

Family / individual medical

history of AD or stroke.

Have hyperglycemia, hypertension, and hyperlipidemia.

Suffering from memory

loss and cognitive decline.

Our Services

Cognitact provide a blood-based protein biomarkers analysis service for AD early detection— PlasmarkAD^®. PlasmarkAD^® achieves early detection of AD at 5-10 years with the accuracy of over 96% before symptoms appear.

ProjectB

HK$299.00 ~~HK$999.00~~

View Details

Our Mission

We are aspired to enable the public to receive more convenient and accurate predictions and diagnoses in neurodegenerative diseases. We hope to bring forth the next generation of Alzheimer's disease prediction and diagnostic tools for everyone through translating big data discoveries into molecular diagnostics.

Latest News

Follow all the latest updates and press release of Cognitact

2023-11-13 17:43:46

Shopping Cart

Molecular Detection of
Neurodegenerative Diseases

Molecular Detection of
Neurodegenerative Diseases

Molecular Detection of
Neurodegenerative Diseases

Top-notch Technology

Top-notch Technology

Top-notch Technology

Blood Protein Detection

Blood Protein Detection

Blood Protein Detection

Ascertain the Risk
5-10 Years Prior to Onset

Ascertain the Risk
5-10 Years Prior to Onset

Ascertain the Risk
5-10 Years Prior to Onset